+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07812090

Study of Oral BGE-102 Alone or with Anti-VEGF Therapy for Center-Involved Diabetic Macular Edema Evaluating Vision, Safety, and Tolerability

Led by BioAge Labs, Inc. · Updated on 2026-10-27

180

Participants Needed

16

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effects of BGE-102 on vision changes in adults with center-involved diabetic macular edema CI-DME. This phase 2 study aims to assess how BGE-102, alone or combined with an anti-vascular endothelial growth factor anti-VEGF drug, affects ocular health and vision over a 12-week treatment period. The study also monitors the safety and tolerability of BGE-102. Participants will be randomly assigned to one of three groups BGE-102 capsules taken once daily combined with sham injections, BGE-102 capsules combined with anti-VEGF injections every four weeks, or placebo capsules combined with anti-VEGF injections every four weeks. The total treatment lasts up to 12 weeks. The study includes a screening period up to 4 weeks and a 4-week follow-up after treatment ends. During the approximately 20-week study, participants attend visits every two weeks for the first month of treatment, then every four weeks until week 16. Researchers will evaluate vision using best corrected visual acuity at week 12 as the main outcome. Safety is also carefully monitored through adverse event tracking up to week 16. Participants may undergo eye charts, retinal scans, and other ocular assessments throughout the study.

CONDITIONS

Brief Title

A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema

Research Team

C

Central Recruiting

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here